CASE REPORT

Accidental overdose in the deep shade of night: a warning on the assumed safety of ‘natural substances’

Andrew Chadwick, Abigail Ash, James Day, Mark Borthwick

SUMMARY
There is an increasing use of herbal remedies and medicines, with a commonly held belief that natural substances are safe. We present the case of a 50-year-old woman who was a trained herbalist and had purchased an ‘Atropa belladonna (deadly nightshade) preparation’. Attempting to combat her insomnia, late one evening she deliberately ingested a small portion of this, approximately 50 mL. Unintentionally, this was equivalent to a very large (15 mg) dose of atropine and she presented in an acute anticholinergic syndrome (confused, tachycardic and hypertensive) to our accident and emergency department. She received supportive management in our intensive treatment unit including mechanical ventilation. Fortunately, there were no long-term sequelae from this episode. However, this dramatic clinical presentation does highlight the potential dangers posed by herbal remedies. Furthermore, this case provides clinicians with an important insight into potentially dangerous products available legally within the UK. To help clinicians’ understanding of this our discussion explains the manufacture and ‘dosing’ of the A. belladonna preparation.

BACKGROUND
‘Atropa belladonna’, or ‘deadly nightshade’, is often associated with literary references describing the use of the plant by women to induce mydriasis to make themselves appear more seductive. Atropine is commonly used in Western medicine, for example, in the treatment of bradycardia. In herbal medicine, the anticholinergic effects of A. belladonna are used to alleviate ‘nervous’ pain, muscle spasm and to reduce secretions. Most cases of belladonna poisoning occur from direct ingestion of the plant’s berries. However, our case describes the first published account of accidental atropine poisoning where atropine was obtained for professional herbalist purposes. It therefore highlights important safety considerations. The product involved was purchased legally for the intended beneficial effects, yet a small volume, just 50 mL, was able to produce almost fatal effects.

DIFFERENTIAL DIAGNOSIS
Atropine acts as a competitive antagonist for the muscarinic acetylcholine receptors. Therefore, at its poisoning dose, it produces an almost complete block of the parasympathetic nervous system. This allows the symptoms to be predicted with the classic descriptive terms presented in table 1. Most cases of atropine poisoning, intentional or otherwise, occur due to the ingestion of berries or plant material. Children are often poisoned by inadvertently ingesting A. belladonna berries. The subsequent anticholinergic toxidrome can have varying degrees of severity. Adult atropine poisoning is less commonly reported. Cases of mistaking A. belladonna for blueberries, or deliberate ingestion to cause self-harm, have been reported. Atropine poisoning has also been associated with rhabdomyolysis, pancreatitis and a subdural haematoma.

However, given the wide variety of symptoms mentioned above, any condition that can cause a
combination of tachycardia, altered mental status, urinary retention and possibly seizures can be included in the differential diagnosis of atropine poisoning.

We will consider, first, other poisons that can mimic this and, second, non-poisoning differential diagnoses.

Some poisons will cause a true anticholinergic response. In our case, the plant was deadly nightshade, however, there are also woody and common nightshade plants. Furthermore Jimson weed (a plant occasionally smoked recreationally) contains anticholinergic alkaloids at high enough concentration to poison. Finally medicinal atropine (or other anticholinergic drugs) can be taken in overdose through accident or intentionally. More commonly, though, poisons will have a degree of anticholinergic response but also other effects. The most significant class of drugs of this type are the tricyclic antidepressants. Although they will cause an anticholinergic syndrome, their effects on cardiac sodium channels cause the classic QRS prolongation and their \( \alpha \)-blockade can result in significant hypotension. These clinical aspects tend to predominate in their poisoning. Phenothiazine derived drugs also cause anticholinergic affects. This chemical class makes up a variety of anti-cholinesterase (eg, proclophorazaine) and antipsychotic (eg, chlorpromazine) medications. Although theoretically useful of these substances could present as an anticholinergic syndrome, their hypotensive and sedating actions tend to predominate. Many of the symptoms from anticholinergic poisoning result from unopposed sympathetic system activity, therefore, poisoning by sympathomimetics can result in a very similar clinical paradigm. Hence, overdose of methamphetamine, cocaine, or even cough mixtures (due to the phenylephrine) are an important differential; however, a key difference is that these all tend to produce excessive sweating and the mydriasis is less marked. Furthermore, methamphetamine often present with more prominent psychosis and cocaine is marked by extreme perspiration and restlessness. A final key overdose differential in a patient who is hyperthermic, agitated and tachycardic, is salicylate poisoning. This in part is because of the ease of its supply. Aspirin poisoning tends to produce tinnitus, nausea and the classical blood gas changes of progression from respiratory alkalosis to metabolic acidosis, all of which can differentiate it from the anticholinergic poisonings.

Important non-overdose differentials to consider include sepsis (particularly from a neurological source), serotonin syndrome and neuroleptic malignant syndrome. Central nervous system (CNS) infection can cause all the symptoms listed above but the temporal progression of the symptoms can often help differentiate this; the delirium associated with anticholinergic poisonings tends to have a sharp onset time as opposed to a more gradual action of inflammatory processes. Serotonin syndrome occurs in response to excessive CNS serotonin levels. This can be seen in overdose of the selective serotonin reuptake inhibitors (SSRIs), but their very large therapeutic window makes this a rare presentation. Therefore, it is more commonly seen as a side effect when SSRIs are taken over a longer period of time and augmented either by a dose increase or further medications (eg, ondansetron). It can also be seen in Carcinoid syndrome from serotonin-secreting tumours. Serotonin syndrome will result in a flushed, agitated and hyperpyrexic patient. However, it also causes sweating and neuromuscular hyper-reactivity (tremor, hyper-reflexia, myoclonus), which differentiate it from anticholinergic poisoning. Finally, neuroleptic malignant syndrome is a key differential. This rare syndrome can occur with any of the antipsychotic medications or on withdrawal of Parkinson’s treatments. The pathogenesis is thought to revolve around dopamine inactivity in the hypothalamus (either via receptor blockade or loss of substrate, respectively). This causes a hyperpyrexia, autonomic dysregulation (mimicking any of the symptoms above) and Parkinson’s symptoms. These latter symptoms again act as a differentiator from both anticholinergic poisoning and also serotonin syndrome.

**TREATMENT**

As mentioned in our case presentation, she was suffering from very severe agitation. Therefore, to ensure her safety, and to facilitate safe investigation of her state, we proceeded to immediate intubation. We performed this using 100 μg fentanyl, 170 mg propofol and 60 mg rocuronium, sedation was then maintained with propofol and fentanyl infusions (12 mg/h and 50 μg/h, respectively). During her 10 h of treatment, 4.5 L of crystalloid rehydration occurred.

However, in most cases of atropine poisoning, the cerebral side effects are not so severe as to merit immediate sedation and airway protection. Indeed, as shown in table 2, this is a marker of very severe overdose.

**Table 1** Symptoms of anticholinergic syndrome

<table>
<thead>
<tr>
<th>Description</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red as a beet</td>
<td>Compensating for the loss of sweat leads to excessive vasodilatation of the skin to maximise heat loss</td>
</tr>
<tr>
<td>Dry as a bone</td>
<td>Muscarinic action causes sweat glands to activate, therefore, anticholinergics cause anhidrosis (absence of sweat)</td>
</tr>
<tr>
<td>Hot as a hare</td>
<td>The removal of the normal thermal haemostasis mechanisms often results in high fever</td>
</tr>
<tr>
<td>Blind as a bat</td>
<td>Pupillary constriction and accommodation rely on muscarinic receptors, therefore, anticholinergics cause pupillary dilation and blurry vision</td>
</tr>
<tr>
<td>Mad as a hatter</td>
<td>The loss of central nervous system muscarinic receptor action can lead to a range of symptoms from anxiety, delirium, visual hallucinations through to seizures and coma</td>
</tr>
<tr>
<td>Full as a drum</td>
<td>Both the detrusor muscle and urinary sphincter are under muscarinic control and therefore anticholinergics will lead to a decreased signal to urinate and an increase in urinary retention</td>
</tr>
<tr>
<td>Non-nomemonic</td>
<td>Loss of muscarinic receptors means there is unopposed sympathetic action on the heart, giving tachycardia. There is also slowing (or complete absence) of bowel sounds</td>
</tr>
</tbody>
</table>

**Table 2** Symptoms by severity of atropine poisoning (modified from Toxnet)

<table>
<thead>
<tr>
<th>Mild symptoms</th>
<th>Moderate symptoms</th>
<th>Severe symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dry mouth, urinary retention and constipation</td>
<td>Somnolence, classical mydriasis, flushing, fever and anhidrosis. Mild agitation, hallucinations and confusion</td>
<td>Agitated delirium, psychosis, hallucinations, seizures, hyperthermia and coma</td>
</tr>
</tbody>
</table>
Indeed, in most atropine poisonings there are only mild or moderate symptoms, where supportive management using pro re nata benzodiazepines for agitation or seizures is adequate. There is also evidence that, if a patient can reliably protect their airway and there is recent (<1 h) ingestion of the atropine, activated charcoal may be of benefit.

Physostigmine is a reversible cholinesterase inhibitor; it is a tertiary amine and can therefore cross the blood–brain barrier. This distinguishes it from neostigmine (a more polar quaternary amine), which is used much more commonly to augment reversal of neuromuscular blockade postsurgery or in the treatment of myasthenia gravis. Both drugs work by inhibiting the breakdown of acetylcholine. However, only physostigmine can reverse the significant cerebral effects and can therefore act as an antidote in atropine poisoning, increasing the concentration of acetylcholine to overcome the muscarinic receptor’s competitive inhibition with atropine. Therefore, some people recommend its use in moderate-to-severe poisonings. This may lead to lower rates of intubations and, in one small trial, it was better at controlling delirium and agitation than were benzodiazepines. Physostigmine is limited, however, in three ways; first, it is a rare drug, meaning it is not always immediately available. Second, it has a short duration of action (45–60 min) when compared to atropine (elimination half-life 2 h). Third, it is contraindicated if there is co-ingestion of tricyclic antidepressants due to an increase in the rate of arrhythmias and seizures. Therefore, before using physostigmine, it is important to know the aetiology of the poisoning. It may have a role in helping avoid intubation in certain patients or confirming the suspected diagnosis, however, in most situations, supportive care with possible escalation to sedation and intubation is adequate.

OUTCOME AND FOLLOW-UP
Fortunately, the patient made a full recovery from this incident. Before discharge from hospital, our psychological medicine team interviewed her and confirmed that, though the ingestion was deliberate, the very high dose was accidental and of non-suicidal intent. No long-term follow-up was required.

DISCUSSION
The use of A. belladonna in medicine has a long history. ‘Belladonna extract’ is described in the very first edition of the British Pharmacopoeia (1864). This text defined tincture of belladonna, utilising a preparation technique of belladonna leaf and ‘proof spirit’ (57% alcohol) in proportions of approximately 1:20.

The modern British Pharmacopoeia (BP) uses belladonna leaf and 70% alcohol in proportions of 1:10 to create Belladonna Tincture BP. This standard demands that the tincture contain 0.3 mg alkaloid per ml calculated as hyoscyamine. Atropine is a racemic mixture of the optical isomers D and L-hyoscyamine, with the 1-hyoscyamine isomer being biologically active. The usual dose of Belladonna Tincture BP is 0.5–2 mL, given several times a day, generally as a gastrointestinal antispasmodic.

In this case, the herbalist had access to an A. belladonna preparation supplied by a herbal tincture manufacturer. The manufacturing process employed is very similar to that described for Belladonna Tincture BP. One kilogram of dry belladonna leaf (wild collected) is macerated and cold percolated with 10 L of an alcohol solution. It is not clear how this use of a weaker alcohol solution (45%) affects the alkaloid content, if at all. The final liquor is filtered to remove particulate matter, first through a 10 μ filter, then again through a 1 μ filter, before being bottled for sale in 500 mL bottles.

It is worth noting that the sale of the product is entirely legal. The medicines (retail sale of herbal remedies) order 1977 SI 2130 makes provision for exemptions for herbalists, allowing them to be in possession of and to supply a wide range of products in the course of their practice. Herbal medicines can be sold/supplied by the herbalist following a one-to-one consultation between the herbal practitioner and the client, provided the prescription remains within dose and route of administration limits outlined in Part II of the order. The herbalist can also exceed these limits provided the prescription order generated is fulfilled in a registered pharmacy by or under the supervision of a pharmacist. There is no mandatory training or registration for individuals wishing to practice as a herbal practitioner, although there are several courses available and voluntary registration schemes run by the array of bodies that represent herbalists. Herbalists are able to obtain stock products from several manufacturers and distributors, in the absence of a specific state registration scheme.

In the present case, the bottle had been unopened prior to the incident, so it was possible to calculate the volume consumed—this was found to be approximately 50 mL. Using an estimate of 0.3 mg/mL alkaloid content, the patient dose was estimated to be in the region of 15 mg of alkaloid. Given that hyoscyamine readily becomes racemic during the extraction process, this would mean that the patient took approximately 15 mg of atropine orally, although there is clearly a significant margin for error. To help contextualise this, the exact fatal dose of atropine is not known, indeed it has a relatively large margin of safety (LD10, 453 mg) however, 10–20 mg of atropine is incapacitating and, in children, doses of <10 mg have proved fatal.

To the best of our knowledge, this is the first reported incident of life-threatening atropine poisoning from ingestion of purchased herbal tincture A. belladonna preparation in the world literature. The case provides an important warning about the easy and legal availability of potentially lethal preparations and therefore we have not only described the case but have also detailed the manufacture and purchase of the substance.

Learning points

- The care of atropine poisoning is predominantly excellent supportive care with benzodiazepines to treat agitation, though administration of physostigmine should be considered. Patients may require intubation and ventilation for their agitation.
- The presentation of an acute confusional state is common to the medical take and this case highlights the importance of obtaining a full drug history including use of herbal preparations.
- Finally, and most significantly, our case highlights the availability of potentially lethal substances that are easily obtainable with relatively minimal legal safeguards or specifications relating to the herbal remedy industry.

Acknowledgements The authors would like to acknowledge Hannah Smorzaniuk, pharmacist at the John Radcliffe Hospital, Oxford, who researched much of the data regarding the dosage of Belladonna Tincture during the clinical case.
Contributors AC was the lead author writing the case summary. AA provided the literature search on atropine poisoning and wrote large amounts of the discussion. MB provided the legal/procedural research on the production of herbalist tinctures and also wrote large amounts of the discussion. JD helped write the concluding statements and provided edits throughout the whole document.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

25 https://www.pharmacopoeia.com/